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Summary at a glance: 
In a large ILD cohort, all of whom had undergone right heart catheterization (RHC), the recent 
European Society of Cardiology/European Respiratory Society echocardiography screening 
recommendations correctly classified the majority of patients with PH. However, 40% of 
patients were misclassified as ‘low probability’ of PH, when PH was confirmed on subsequent 
RHC. 
 
 
 
2 
 
ABSTRACT 
 
Background and objectives: 
In interstitial lung disease (ILD), pulmonary hypertension (PH) is a major adverse prognostic 
determinant. Transthoracic echocardiography (TTE) is the most widely used tool when 
screening for PH, although discordance between TTE and right heart catheter (RHC) measured 
pulmonary haemodynamics is increasingly recognised. We evaluated the predictive utility of 
the updated European Society of Cardiology/European Respiratory Society (ESC/ERS) TTE 
screening recommendations against RHC testing in a large, well-characterised ILD cohort.  
Methods:  
Two hundred and sixty five consecutive patients with ILD and suspected PH underwent 
comprehensive assessment, including RHC, between 2006 and 2012. ESC/ERS recommended 
tricuspid regurgitation (TR) velocity thresholds for assigning high (>3.4 m/s), intermediate 
(2.9-3.4 m/s) and low (<2.8 m/s) probabilities of PH were evaluated against RHC testing. 
Results:  
RHC testing confirmed PH in 86% of subjects with a peak TR velocity  > 3.4 m/sec, and 
excluded PH in 60% of ILD subjects with a TR velocity < 2.8 m/sec. Thus, the ESC/ERS 
guidelines misclassified 40% of subjects as ‘low probability’ of PH, when PH was confirmed 
on subsequent RHC. Evaluating alternative TR velocity thresholds for assigning a ‘low 
probability’ of PH did not significantly improve the ability of TR velocity to exclude a diagnosis 
of PH.   
Conclusion:  
In patients with ILD and suspected PH, currently recommended ESC/ERS TR velocity 
screening thresholds were associated with a high positive predictive value (86%) for confirming 
PH, but were of limited value in excluding PH, with 40% of patients misclassified as ‘low 
probability’ when PH was confirmed at subsequent RHC. 
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Short title: Pulmonary hypertension in ILD 
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INTRODUCTION 
 
In many interstitial lung diseases (ILDs), the presence of pulmonary hypertension (PH) is a 
major adverse prognostic determinant associated with increased morbidity and mortality (1, 2). 
Measures of pulmonary vascular disease are strongly predictive of early mortality across a 
spectrum of ILDs, irrespective of histopathologic subtype, or severity of underlying interstitial 
disease (3, 4). While right heart catheter (RHC) testing remains the gold standard diagnostic 
investigation for PH, selecting whom to refer for this invasive and resource-limited procedure 
can be challenging.  
 
Transthoracic echocardiography (TTE) is the most widely utilised screening test for PH, 
providing a non-invasive estimation of the pulmonary artery systolic pressure (PASP), and 
crucial information about right ventricular (RV) size and function. While TTEPASP (estimated 
from Doppler measured tricuspid transvalvular gradient via the modified Bernoulli equation) 
correlates strongly with directly measured RHCPASP under controlled study conditions (5-7), 
discrepancies between these measures have been reported in ‘real world’ screening populations 
(8-10), including ILD patients, with differences between RHCPASP and TTEPASP of 10 mmHg 
or more reported in up to 50% of patients (11, 12).   
 
The 2015 European Society of Cardiology/European Respiratory Society (ESC/ERS) 
Guidelines for the diagnosis and treatment of pulmonary hypertension (13) recommend 
Doppler measurement of peak tricuspid regurgitation (TR) velocity (rather than the traditionally 
used TTEPASP) as the primary screening metric for assessing the likelihood of PH. Specific TR 
velocity thresholds (coupled with ancillary TTE findings when required) have been 
recommended to assign high, intermediate and low probabilities of PH. In the current study, 
the largest ILD-PH cohort yet reported, we evaluated the utility of these ESC/ERS TR  
thresholds for predicting the presence of PH (compared against RHC testing), and assessed  
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alternative thresholds which may provide improved  discrimination between the presence and 
absence of PH in our cohort. .   
 
 
 
METHODS 
 
Patient selection 
Consecutive patients with ILD and suspected PH who completed clinical and haemodynamic 
assessment (including RHC testing) between 2006 and 2012 were evaluated. Importantly, only 
patients with clinically suspected PH following review by an expert PH physician (with 
integration of all relevant information including physical examination, TTE, pulmonary 
function tests (PFTs) and other tests where available) proceeded to RHC testing.  All patients 
were under follow-up with the Royal Brompton ILD Unit, , and this research was conducted in 
accordance with the amended Declaration of Helsinki. Institutional ethics review board 
approval was in place for the study (Royal Brompton, Harefield & NHLI REC reference 01-
246). 
 
In accordance with current ESC/ERS recommendations (13), peak TR velocity thresholds for 
assessing the probability of PH were evaluated. Peak TR velocities of >3.4 m/s and ≤2.8 m/s 
(or not measurable) are recommended thresholds associated with a high and low probability of 
PH respectively, while TR velocities of 2.9-3.4 m/s are associated with an intermediate 
probability of PH, and ancillary TTE features should be incorporated into the screening 
algorithm (table 1). Given the retrospective nature of the study, not all ancillary features were 
available, so an a priori decision was made to use the presence of RV dilatation and/or 
dysfunction on TTE as a surrogate in lieu of the ancillary features recommended by the 
ESC/ERS guidelines. Thus, strictly speaking, we assessed ‘modified’ ESC/ERS criteria for 
predicting the presence or absence of PH in our cohort.  
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Measurements 
RHC was performed using standard techniques (14), with mean pulmonary artery pressure 
(mPAP) measured at rest in all patients. PH was defined as mPAP ≥ 25 mmHg (13). Two-
dimensional TTE using Doppler colour flow imaging was performed, including measurement 
of the peak TR velocity. TTEPASP was calculated using the modified Bernoulli equation 
(PASP=4 x TR2 + right atrial pressure) (7), with right atrial pressure (RAP) estimated on the 
basis of inferior vena cava size and movement with respiration (15). RV  size was  assessed 
using the mid and/or basal chamber end diastolic dimensions, while RV function was measured 
using tricuspid annular plane systolic excursion and/or tissue Doppler imaging (16).  
 
All patients underwent thoracic computed tomography (CT), performed in the supine position 
at full inspiration, with scans anonymized by an independent investigator not involved in 
subsequent scoring. The presence and extent of ILD on CT was assessed independently by two 
radiologists (SLFW and JJ), blinded to clinical and haemodynamic data. In order to determine 
whether measures of tricuspid regurgitation were influenced by the severity of ILD, extent of 
ILD on CT was classified as limited (<20%), extensive (>20%) or indeterminate, as previously 
described (17). Where CT ILD extent was judged as indeterminate, forced vital capacity percent 
predicted (FVC%) using a threshold of 70% was used to classify limited or extensive ILD. 
PFTs were performed (Jaeger Masterscreen; Cardinal Health UK 240 Ltd), with predicted 
values calculated according to ATS/ERS guidelines (18-21).   
 
Statistical Analysis 
All analyses were performed using STATA statistical software (version 14.0; Stata Corp., 
College Station, TX, USA). Data were expressed as means with standard deviation (for 
normally distributed data) or medians with ranges (for non-normally distributed data). Group 
comparisons were made using the Student t test, Wilcoxon rank-sum test, and χ2 statistics where 
appropriate. ROC curve analysis was performed to assess the discriminatory ability of the 
currently recommended TR thresholds (coupled with RV characteristics on TTE) to distinguish 
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between the presence and absence of PH, with an area under the curve (AUC) of 1.0 indicating 
perfect discrimination between patients with and without PH, while a value of 0.5 indicates no 
discriminatory value from the test.   
 
 
 
RESULTS 
 
Baseline characteristics 
Two hundred and sixty five consecutive patients (mean age 60.8±11.6 years; 143 females) with 
ILD and suspected PH who underwent RHC were evaluated. ILD clinical diagnoses included 
connective tissue disease (CTD) associated ILD (n=94; 35%), idiopathic pulmonary fibrosis 
(IPF: 63; 24%), sarcoidosis (38; 14%), other idiopathic interstitial pneumonias (IIP; including 
idiopathic non-specific interstitial pneumonia and cryptogenic organising pneumonia) (31; 
12%), and other ILDs (including chronic hypersensitivity pneumonitis, drug induced ILD, and 
unclassifiable ILD) (39; 15%). The majority of ILD diagnoses were confirmed at 
multidisciplinary team review. ILD was classified as extensive in 199 patients (75%) and 
limited in 66 (25%), with good agreement between radiologists (kappa 64.0%; p<0.01). There 
was no correlation between ILD severity (as determined by FVC% predicted) and mPAP 
(r=0.00; p=0.70) (figure 1). Baseline characteristics are presented in table 2.  
 
Haemodynamic assessment 
 Following RHC, PH was confirmed in 194 patients (73%; average mPAP 37.2±9.2 mmHg), 
with an elevated pulmonary capillary wedge pressure (>15 mmHg) in 54 patients (28%) in this 
group. TTE results were available for review in all patients, with TR able to be measured in 
215 (81%) patients, and RV size and function documented in 250 (94%). There was a moderate 
correlation between peak TR velocity and RHC measured mPAP (r=0.48; p<0.01) (figure 2). 
As reflected by ROC curve analysis, peak TR velocity provided moderate discriminatory value 
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in distinguishing between the presence and absence of PH in our cohort (AUC 0.73; 95% 
confidence interval 0.68 to 0.79; p<0.01) (figure 3).  
 
On TTE, 138 patients had a peak TR velocity of >3.4 m/s, with PH confirmed on subsequent 
RHC in 118 patients (yielding a sensitivity of 61%, and PPV of 86%) (table 3a). The 
combination of a TR velocity of >3.4 m/s coupled with the presence of RV dilatation and/or 
dysfunction improved sensitivity and PPV to 85% and 90% respectively. Peak TR velocity was 
≤2.8 m/s (or not measurable) in 78 patients, with normal RV size and function in 43 (55%). In 
this group of 43 patients classified as ‘low probability’ of PH by the modified ESC/ERS 
criteria,17 (40%) had PH present on subsequent RHC, while in the remainder (26 patients; 
60%) PH was excluded on RHC.  Therefore in our cohort, the modified ESC/ERS criteria for 
assigning a ‘low probability’ of PH were associated with a sensitivity and positive predictive 
value for excluding PH of 74% and 60% respectively (table 3a). Comparing the correctly 
classified (n=26) and misclassified (n=17) ‘low probability’ cohorts revealed a lower FEV1 and 
FVC % predicted in the misclassified cohort, but there were no other significant differences in 
demographic or clinical data to explain the relatively high misclassification rate (table 4). In 
patients with a TR velocity of <2.8 m/s (or not measurable) and RV dilatation or dysfunction 
on TTE, the majority (25/35; 71%) had PH confirmed on subsequent RHC.  
 
In 49 patients, TR velocity was between 2.9-3.4 m/s. PH was confirmed on RHC in 34 patients 
(69%), in whom 17 (50%) had RV dilation and/or dysfunction on TTE. Fifteen patients (31%) 
had PH excluded at RHC, eight (53%) of whom had normal RV size and function on TTE. In 
our cohort with an intermediate probability of PH based on TR velocity, the presence of RV 
dilatation and/or dysfunction was of limited value in further refining the probability of PH (table 
3a). 
 
 
Alternative TR velocity thresholds in assessing for PH 
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Evaluating alternative TR thresholds for assigning PH probabilities resulted in the expected 
‘trade offs’ between sensitivity and specificity. Using a TR velocity threshold of 3.2 m/s by 
which to define a ‘high probability’ of PH improved sensitivity, but reduced the specificity due 
to an increased number of false positive cases (table 3b). Importantly, using a lower TR velocity 
(eg 2.4 m/s) for assigning ‘low probability’ of PH  still resulted in approximately 30% of 
patients with RHC proven PH being misclassified as low probability by TR velocity thresholds 
alone (table 3b). 
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DISCUSSION 
 
Pulmonary hypertension occurring in association with ILD is an ominous development, with 
measures of pulmonary vascular disease predictive of early mortality (3, 4). Despite this 
morbidity and mortality burden, accurate ILD-PH prevalence data remains elusive, in part due 
to the confounding effects of ILD on conventional PH screening measures. Our study, the 
largest ILD-PH cohort yet reported and the first to evaluate the recent ESC/ERS TTE screening 
recommendations (albeit with several important modifications), highlights strengths and 
limitations of the current screening approach. While the modified ESC/ERS criteria correctly 
identified PH in the majority of patients, a significant minority (40%) were misclassified as 
‘low probability’ of PH, when PH was confirmed on subsequent RHC.  Assessing alternative 
TR thresholds by which to more accurately define ‘low probability’ of PH did not yield 
significantly better cut-offs, with up to 30% of patients in our cohort still misclassified as ‘low 
probability’ even at very low TR velocity thresholds (eg <2.4 m/s). Our results suggest that in 
the setting of clinically suspected ILD-PH, TR velocity (even in the presence of normal RV 
size and function), may not be sufficiently robust to confidently exclude a diagnosis of PH.   
 
Despite its limitations, TTE remains the most widely used screening test for suspected PH. 
While several studies have demonstrated excellent correlation between TTEPASP and RHCPASP 
(5-7), a number of contemporary studies have questioned the strength of this relationship, 
particularly when applied to ‘real world’ screening populations (7-9). Several authors have 
reported a discordance between TTEPASP and RHCPASP of ≥10 mmHg in approximately 50% of 
patients (7-9), including patients with IPF and other ILDs (11, 12). In the setting of advanced 
lung disease, Arcasoy reported estimation of TTEPASP to be possible in only a minority of 
patients (44%), and even then, TTEPASP was accurate (within 10 mmHg of RHCPASP) in only 
half of patients (11). In an IPF population, Nathan reported similar results, with TTEPASP 
accurately reflecting RHCPASP in only 40% of patients (12).  
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In our cohort, a peak TR velocity of >3.4 m/s correctly predicted PH in almost 90% of patients; 
a diagnostic yield significantly greater than many previous studies. This higher positive 
predictive value may be explained, at least in part, by differences in patient recruitment, in 
particular the importance of expert clinical assessment in identifying patients with a high pre-
test probability of PH. Previous ILD-PH studies have typically included patients undergoing 
lung transplant assessment where the decision to perform RHC was part of standardised clinical 
protocol. In contrast, we included patients in whom expert clinical assessment judged the 
likelihood of PH to be high enough to warrant proceeding to RHC, and as such, the PH 
prevalence in our cohort was significantly higher (73%) compared to previous studies (with 
prevalence ranges of 25-51%) (11, 12, 25). Through this application of Bayesian principles, we 
were able to identify a population with a high pre-test probability for PH, and thus enable more 
appropriate triaging for invasive and resource limited right heart catheterisation.  
 
Despite impressive results for TTE in accurately predicting PH in a majority of patients, 40% 
of our cohort  classified as ‘low probability’ of PH by the ESC/ERS guidelines had PH 
confirmed on subsequent RHC, and the reason for this remains difficult to explain. . Anatomic 
changes in chest wall configuration and cardiac orientation (with resultant poor acoustic 
windowing of the TR jet) may explain the limitations of TTE in assessing pulmonary pressures 
in chronic obstructive pulmonary disease (26, 27), but whether these same factors apply in ILD 
is not known. In our cohort, , the ILD extent was similar in the correctly and incorrectly 
classified ‘low probability’ groups (despite a greater reduction in FEV1 and FVC % predicted 
in the incorrectly classified subgroup; table 4), suggesting that ILD extent may not have 
influenced TR interpretation. Whether the presence of co-existent emphysema impacted the 
accuracy of TTE warrants further evaluation.   
Our findings expand on previously reported data in two important areas. Firstly, there was a 
relatively high prevalence (28%) of raised pulmonary capillary wedge pressure on RHC testing, 
suggesting a component of ‘post capillary’ PH which may be amenable to therapies directed at 
optimising left heart function and improving symptoms. Our results also demonstrate the poor 
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correlation between ILD extent and pulmonary haemodynamics, reflecting the frequent 
‘uncoupling’ of interstitial and pulmonary vascular disease processes. PH was present in 1/3 of 
our cohort with ‘milder’ ILD (defined as a FVC >70% predicted), and these findings should 
further discount the outdated perception that PH occurs only in the setting of advanced ILD. 
Finally, the incorporation of additional non-invasive investigations (such as brain natriuretic 
peptide, PFTs, and vascular dimensions on thoracic CT imaging), has shown some promise in 
better defining the presence of ILD-PH (particularly in the setting of IPF), and warrants more 
detailed evaluation (28-31). 
 
Inherent in the retrospective design of this study are limitations involved with respect to 
selecting patients to undergo RHC. We aimed to mirror real world clinical practice where 
patients are selected for RHC testing based on clinically suspected PH (including TTE findings) 
following expert PH physician review. While the decision to proceed with invasive testing will 
inevitably vary between institutions, we sought to minimise bias by evaluating consecutive 
patients with a range of ILD diagnoses following comprehensive assessment. Finally, we did 
not strictly adopt ESC/ERS ancillary TTE findings, in part due to the retrospective nature of 
the study as not all these TTE findings were consistently reported. We elected instead to adopt 
a pragmatic  approach of incorporating the presence of RV  dysfunction and/or dilatation, as 
these data are generally readily available and well understood.  
 
 
In conclusion, our study highlights the need for readily accessible, accurate screening tools to 
assess for ILD-PH, and the continued pivotal role for RHC in confirming the diagnosis. In a 
large heterogeneous ILD population, currently recommended TTE screening thresholds 
performed strongly in confirming a diagnosis of PH, although were associated with a significant 
misclassification rate  when used in isolation to exclude PH.  
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Table 1. Echocardiographic probability of pulmonary hypertension (PH) in symptomatic 
patients with a suspicion of PH, as recommended by the 2015 European Society of 
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Cardiology/European Respiratory Society Guidelines for the diagnosis and treatment of PH 
(13). 
 
Peak tricuspid regurgitation 
velocity (m/s) 
Presence of other TTE          
PH signs1 
Probability of PH 
≤2.8 or not measurable No Low 
      
≤2.8 or not measurable Yes 
Intermediate 
2.9-3.4 No 
      
2.9-3.4 Yes 
High 
>3.4 Not required 
 
1 Ancillary TTE signs suggesting PH include: right ventricle (RV)/left ventricle basal diameter ratio >1.0; flattening 
of the interventricular septum; RV outflow Doppler acceleration time <105 msec and/or midsystolic notching; early 
diastolic pulmonary regurgitation velocity >2.2 m/sec; pulmonary artery diameter >25 mm;  inferior vena cava 
diameter >21 mm with decreased inspiratory collapse;  right atrial area (end-systole) >18 cm2 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2. Baseline clinical and demographic information. 
  
Entire group 
(n=265) 
PH            
(n=194) 
No PH        
(n=71) 
p value 
19 
 
Age, yr 60.8 (11.6) 61.1 (12.0) 59.9 (10.5) 0.46 
Gender, M:F 122:143 89:105 33:38 0.93 
Body mass index  28.2 (5.4) 28.5 (3.9) 27.9 (6.6) 0.87 
 
ILD diagnosis      
CTD (n) 94 57 37   
IPF 63 46 17   
Other IIP 31 27 4   
Sarcoid 38 36 2   
Other ILD 39 28 11   
       
ILD extent      
limited:extensive 66:199 46:148 20:51 0.36 
       
Right heart catheter      
mPAP (mmHg) 32.4 (11.3) 37.2 (9.2) 19.3 (3.6) <0.01 
PVR (Wood Units) 5.7 (4.1) 7.1 (4.1) 2.4 (1.3) <0.01 
CO (L/min/m2) 4.5 (1.3) 4.3 (1.4) 4.9 (1.2) 0.02 
PCWP (mmHg) 9.9 (4.6) 10.3 (4.8) 9.1 (4.1) 0.10 
       
Echocardiography      
TR velocity (m/s) 3.6 (6.4) 3.8 (61.0) 3.2 (5.2) <0.01 
RVSP (mmHg) 62.1 (19.4) 66.7 (18.5) 47.2 (14.0) <0.01 
PacT (ms) 80.7 (25.5) 78.1 (25.0) 88.8 (25.8) 0.02 
RV dysfunction  118 104 14 <0.01 
RV dilation 135 117 18 <0.01 
RA dilation  91 82 9 <0.01 
       
Pulmonary function 
tests      
FEV1% 60.2 (20.2) 58.0 (18.4) 66.1 (23.6) <0.01 
FVC% 64.1 (22.3) 63.3 (20.4) 66.5 (26.8) 0.31 
DLco% 28.6 (12.6) 26.6 (11.2) 34.0 (14.5) <0.01 
Kco% 55.0 (17.5) 52.0 (16.7) 63.2 (17.2) <0.01 
PaO2 (kPa) 8.3 (2.0) 7.8 (1.7) 9.6 (2.0) <0.01 
Aa gradient  5.5 (2.0) 6.0 (1.7) 4.1 (2.0) <0.01 
 
Abbreviations: PH=pulmonary hypertension, CTD=connective tissue disease, IPF=idiopathic pulmonary fibrosis, 
IIP=idiopathic interstitial pneumonia, mPAP=mean pulmonary artery pressure, PVR=pulmonary vascular 
resistance, CO=cardiac output, PCWP=pulmonary capillary wedge pressure, TR=tricuspid regurgitation, 
RVSP=right ventricular systolic pressure, PacT=pulmonary acceleration time, RV=right ventricle, RA=right atrium, 
BNP=brain natriuretic peptide, DLco=diffusing capacity of the lung for carbon monoxide, FEV1=forced expiratory 
volume in one second, FVC= forced vital capacity, DLco= diffusing capacity of the lung for carbon monoxide, Kco= 
diffusing capacity corrected for alveolar volume, PaO2=partial pressure of oxygen, Aa gradient=Alveolar-arterial 
oxygen gradient, PA=pulmonary artery, mm=millimeters, 6MWT=6 minute walk test  
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Table 3. Sensitivity, specificity, positive and negative predictive values of peak tricuspid 
regurgitation (TR) thresholds in assigning probabilities of pulmonary hypertension: a) as 
recommended by ESC/ERS guidelines and b) evaluation of alternative peak TR velocity 
thresholds for assigning ‘high’ and ‘low’ probabilities of PH in our cohort 
a) 
TR velocity 
Sensitivity Specificity PPV NPV 
(95% CI) (95% CI) (95% CI) (95% CI) 
<2.8 m/s (or not measurable)* 
74% (57-88) 60% (44-75) 60% (44-75) 74% (57-88) 
-with normal RV size & function 
       
2.9-3.4 m/s     
with normal RV size & function * 62% (32-86) 50% (32-68) 32% (15-54) 77% (55-92) 
 with RV dysfunction &/or dilatation†  50% (32-68) 62% (32-86) 77% (55-92) 32% (15-54) 
       
>3.4 m/s† 61% (54-68) 72% (60-82) 86% (79-91) 40% (32-49) 
-with RV dysfunction &/or dilatation 85% (77-91) 42% (20-67) 90% (83-95) 32% (15-54) 
 
b) 
TR velocity 
Sensitivity Specificity PPV NPV 
(95% CI) (95% CI) (95% CI) (95% CI) 
<2.4 m/s (or not measurable)* 
71% (49-87) 58% (39-75) 57% (37-75) 72% (51-88) 
-with normal RV size & function 
       
>3.2 m/s† 70% (63-76) 65% (53-76) 84% (79-88) 44% (38-51) 
 
* Sensitivity, specificity, positive and  negative predictive values in assessing for a diagnosis of ‘No pulmonary 
hypertension’ 
† Sensitivity, specificity, positive and negative predictive values in assess for a diagnosis of ‘pulmonary 
hypertension’ 
 
Abbreviations: TR=tricuspid regurgitation, CI=confidence interval, PPV=positive predictive value, NPV=negative 
predictive value, RV=right ventricle 
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Table 4. Comparison of clinical characteristics between patients who were correctly or 
misclassified as ‘low probability’ of PH by current ESC/ERS TTE screening recommendations 
  
Correctly classified      
(n=26) 
Misclassified     
(n=17) 
p value 
Age, yr 57.2 (9.4) 51.6 (9.2) 0.08 
Gender, M:F 6:20 3:14 0.60 
      
ILD diagnosis     
CTD (n) 20 8   
IPF 3 1   
Other IIP 1 1   
Sarcoid 0 5   
Other ILD 2 2   
      
ILD extent     
limited:extensive 12:14 5:12 0.23 
      
Right heart catheter     
mPAP (mmHg) 17.4 (3.2) 34.9 (10.6) <0.01 
PVR (Wood Units) 1.9 (0.8) 4.9 (2.1) <0.01 
CO (L/min/m2) 4.8 (1.2) 4.5 (0.8) 0.40 
PCWP (mmHg) 8.9 (3.4) 11.4 (6.8) 0.20 
      
Echocardiography     
TR velocity (m/s) 2.5 (0.3) 2.6 (0.2) 0.60 
RVSP (mmHg) 33.4 (7.9) 45.5 (22.6) 0.08 
PacT (ms) 104.8 (29.1) 84.8 (20.1) 0.07 
RV dysfunction  0 0   
RV dilation 0 0   
RA dilation  0 0   
      
Pulmonary function tests     
FEV1% 77.4 (20.9) 50.5 (9.8) <0.01 
FVC% 78.5 (24.3) 57.4 (15.2) <0.01 
DLco% 43.6 (16.5) 35.4 (15.8) 0.14 
Kco% 68.5 (17.5) 67.3 (12.1) 0.80 
PaO2 (kPa) 11.1 (1.6) 8.5 (1.5) <0.01 
Aa gradient (kPA) 2.6 (1.6) 5.3 (1.5) <0.01 
 
Abbreviations: PH=pulmonary hypertension, CTD=connective tissue disease, IPF=idiopathic pulmonary fibrosis, 
IIP=idiopathic interstitial pneumonia, mPAP=mean pulmonary artery pressure, PVR=pulmonary vascular 
resistance, CO=cardiac output, PCWP=pulmonary capillary wedge pressure, TR=tricuspid regurgitation, 
RVSP=right ventricular systolic pressure, PacT=pulmonary acceleration time, RV=right ventricle, RA=right atrium, 
BNP=brain natriuretic peptide, DLco=diffusing capacity of the lung for carbon monoxide, FEV1=forced expiratory 
volume in one second, FVC= forced vital capacity, DLco= diffusing capacity of the lung for carbon monoxide, Kco= 
diffusing capacity corrected for alveolar volume, PaO2=partial pressure of oxygen, Aa gradient=Alveolar-arterial 
oxygen gradient, PA=pulmonary artery, mm=millimeters, 6MWT=6 minute walk test  
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